Niels van de Roemer

Learn More
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the(More)
Multiple genetic events and subsequent clonal evolution drive carcinogenesis, making disease elimination with single-targeted drugs difficult. The multiplicity of gene mutations derived from clonal heterogeneity therefore represents an ideal setting for multiepitope tumor vaccination. Here, we used next generation sequencing exome resequencing to identify(More)
In his opening lecture, Ira Mellman (Genentech, San Francisco, USA) introduced the current landscape of immunotherapeutic strategies comprising of checkpoint inhibitors, reversing tumor immunosuppression, vaccines and adoptive T cell therapies (ACT). 1 He further underlined the need for biomarker profiling to guide immunotherapeuties against cancer which(More)
Multiple genetic events and subsequent clonal evolution drive carcinogenesis, making disease elimination with single-targeted drugs difficult. The multiplicity of gene mutations derived from clonal heterogeneity therefore represents an ideal setting for multiepitope tumor vaccination. Here, we used next generation sequencing exome resequencing to identify(More)
  • 1